For the fourth year in a row we invite you to interact around research and innovation in the oncology area. How can new ideas be created by working cross borders? How can industry, academia and the healthcare sector work together?
We are continuing last year’s successful dialogue forums, inspirational lectures and speed-networking in order to find new partnerships. The meeting is a cancer forum for industry, academia and the healthcare sector in the Medicon Valley region. Additionally other interested parties within Lund University, Region Skåne and Medicon Village are welcome. The meeting will be held in English.
Before lunch there will be closed sessions (“Dialogue forum”) where companies and academic researchers have a unique opportunity to discuss specific questions relating to commercialization of research findings. If you have any questions regarding this part of the event, please contact: email@example.com
The meeting opens for the broad audience at 12.00, at Restaurant Inspira, Medicon Village.
Please register no later than Monday 8 May on the webpage:
Location: Restaurant Inspira, Medicon Village, Scheelevägen 2, Lund
12.00 - 12.45 Lunch & Inspirational lecture: ”A lifelong commitment with an unpredictable outcome!?”
Thomas Ek, Superentrepreneur and founder of OBH Nordica
Thomas will describe how he and his brother Peter managed to beat all multi international competitors when they launched a totally unknown brand, OBH Nordica. Key factors such as differentiation, speed, passion and leadership will be explained. Thomas will also talk about social responsibility and how to deal with his worst nightmare - when his brother and business partner became seriously ill in cancer. Thomas Ek is invited by Cancerkompisar.
Location: The auditorium, Medicon Village, Scheelevägen 2, Lund
13.00 - 13.10 Welcome and introduction
13.10 - 14.00 Keynote session: ”Deconstructing cancer and aging in the genomic era”
Carlos Lopez Otin, Professor of Biochemistry and Molecular Biology at the University of Oviedo, Spain
Over recent years, the introduction of new methods for genome sequencing and analysis has allowed the molecular analysis of complex biological processes, such as cancer and aging, under a new perspective. This talk will summarize recent findings of our laboratory derived from genomic studies of patients with cancer and with premature aging syndromes.
14.00 - 14.25 Inspirational Lecture: ” Fighting skin cancer - a collaborative project”
Kari Nielsen, MD, PhD, Lund Melanoma Study Group, Department of Clinical Sciences, Division of Dermatology
Dr. Nielsen will focus on skin cancer research and how collaboration between disciplines and organisations is essential to achieve results.
14.25 - 14.50 Speed networking; Introduction & Coffee
Why is it important to work across borders and in consortia where clinics, universities and industry collaborate in joint projects? And – how do you succeed?
How can SWElife be a partner in your innovative journey?
14.50 - 16.00 Speed networking
16.00 - 16.20 Inspirational Lecture: ”Applicability of Immunitrack platform in identification of cancer specific neoepitope.”
Stephan Thorgrimsen, CEO Immunitrack ApS
Stephan will be speaking about personalized cancer vaccine where patient specific tumor mutations may represent an attractive target for immunotherapy. Here, he will address some of the current advances and challenges and importance of collaborations, and where the technology platform of Immunitrack may help making a difference.
16.20 - 16.40 Inspirational Lecture: ”A liquid biopsy for early detection of ovarian cancer”
Ingrid Hedenfalk, Associate Professor, Lund University, Department of Clinical Sciences, Division of Oncology and Pathology
Ovarian cancer is often called the disease that whispers due to the lack of symptoms. It is generally diagnosed in advanced stages and is therefore associated with a very poor prognosis. Early diagnosis would radically transform survival prospects. The Breast and Ovarian Cancer Genomics research group at LUCC are exploring the combined use of digital droplet PCR and deep sequencing of ovarian cancer-derived DNA in cervical smears for the development of a sensitive, non-invasive diagnostic test, a liquid biopsy. Earlier diagnosis of this lethal disease could radically transform survival prospects. Currently >70% of women diagnosed with ovarian cancer die within five years, but if the cancer is detected early, in stage I, there is a >80% chance of survival.
16.40 - 17.00 Summary/end of meeting
for more information, please download the attached PDF.